Skelaxin News
King Pharmaceuticals Reports Year-End and Fourth-Quarter 2007 ... - PharmaLive.com (press release)
Net sales of SKELAXIN(R) (metaxalone) totaled $114 million during the fourth quarter and $440 million for the year ended December 31, 2007, compared to $113 ...
King Pharma posts higher profit - Guardian
Sales of its Altace blood-pressure drug fell 13 percent to $158 million, while sales of its muscle relaxant Skelaxin were basically flat at $114 million. ...
News and notes from Lake and Marion counties - Orlando Sentinel
The officers returned to Wright's home, where they found a loaded .38-caliber handgun, a small bag of marijuana, and 16 Skelaxin pills, according to the ...
Man accused of pulling gun on school practice field - Orlando Sentinel
The officers returned to Wright's home, where they found a loaded .38-caliber handgun, a small bag of marijuana, and 16 Skelaxin pills, according to the ...
Man accused of pulling gun on school practice field - Orlando Sentinel
The officers returned to Wright's home, where they found a loaded .38-caliber handgun, a small bag of marijuana, and 16 Skelaxin pills, according to the ...
Elan Reports Fourth Quarter and Full-Year 2007 Financial Results - WELT ONLINE
... Months Ended December 31 Twelve Months Ended December 31 2006 US$m 2007 US$m 2006 US$m 2007 US$m 16.1 20.3 Tricor® 52.1 62.5 11.8 11.2 Skelaxin® 36.5 ...
Tuesday's Winners & Losers: King Pharmaceuticals - TheStreet.com
... with the Securities and Exchange Commission that it has terminated its patent infringement lawsuit against CorePharma over the muscle relaxant Skelaxin. ...
Movers Roundup: Supervalu, E-Trade - Forbes
... after the company resolved one of its lingering patent disputes, ending suits against CorePharma LLC relating to King's muscle relaxant drug Skelaxin.
CorePharma to Sell Authorized Generic Skelaxin - FDA news (subscription)
King Pharmaceuticals has terminated patent litigation and entered an agreement giving CorePharma rights to an authorized generic version of Skelaxin. ...
Movers Roundup: Supervalu, E-Trade - Houston Chronicle
... after the company resolved one of its lingering patent disputes, ending suits against CorePharma LLC relating to King's muscle relaxant drug Skelaxin.
Skelaxin RSS Feed